@article{6b4d40c35d634aebb25503268b9f0ecc,
title = "Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants",
abstract = "Introduction The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core (ADNI-NPC) facilitates brain donation, ensures standardized neuropathologic assessments, and maintains a tissue resource for research. Methods The ADNI-NPC coordinates with performance sites to promote autopsy consent, facilitate tissue collection and autopsy administration, and arrange sample delivery to the NPC, for assessment using National Institute on Aging-Alzheimer's Association neuropathologic diagnostic criteria. Results The ADNI-NPC has obtained 45 participant specimens, and neuropathologic assessments have been completed in 36 to date. Challenges in obtaining consent at some sites have limited the voluntary autopsy rate to 58%. Among assessed cases, clinical diagnostic accuracy for Alzheimer disease (AD) is 97%; however, 58% of cases show neuropathologic comorbidities. Discussion Challenges facing autopsy consent and coordination are largely resource related. The neuropathologic assessments indicate that ADNI's clinical diagnostic accuracy for AD is high; however, many AD cases have comorbidities that may impact the clinical presentation, course, and imaging and biomarker results. These neuropathologic data permit multimodal and genetic studies of these comorbidities to improve diagnosis and provide etiologic insights.",
keywords = "Alzheimer's Disease Neuroimaging Initiative, Autopsy consent, Comorbidity, Lewy body, Neuropathology, Pathology heat map",
author = "Franklin, {Erin E.} and Perrin, {Richard J.} and Benjamin Vincent and Michael Baxter and Morris, {John C.} and Cairns, {Nigel J.}",
note = "Funding Information: Data collection and sharing for this project was funded by ADNI ( National Institutes of Health Grant U01 AG024904 ). ADNI is funded by the NIA, NIBIB, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This work was supported by the Charles F. and Joanne Knight Alzheimer's Research Initiative of the Washington University Alzheimer's Disease Research Center , grants P50 AG05681 , P01 AG03991 , and DIAN ( UF1 AG032438 ) from the National Institute on Aging and by the generous support of Fred Simmons and Olga Mohan, the German Center for Neurodegenerative Diseases (DZNE), and a grant from an anonymous foundation. Finally, we acknowledge the licensed neuropathologists within the Division of Neuropathology, Washington University School of Medicine, for assistance with postmortem examinations. Publisher Copyright: {\textcopyright} 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = jul,
day = "1",
doi = "10.1016/j.jalz.2015.05.010",
language = "English",
volume = "11",
pages = "815--822",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
number = "7",
}